{
    "clinical_study": {
        "@rank": "148051", 
        "acronym": "SIGNATURE", 
        "arm_group": {
            "arm_group_label": "LGX818", 
            "arm_group_type": "Experimental", 
            "description": "LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this signal seeking study is to determine whether treatment with LGX818\n      demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic\n      malignancies to warrant further study"
        }, 
        "brief_title": "LGX818 for Patients With BRAFV600 Mutated Tumors", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor and Hematologic Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Patient has a confirmed diagnosis of a select solid tumor (except with a primary\n             diagnosis of melanoma and colorectal cancer (CRC)) or hematologic malignancies and is\n             in need of treatment because of progression or relapse.\n\n          -  Patient's tumor has been evaluated and pre-identified as having a tumor with a\n             BRAFV600 mutation at a CLIA certified laboratory.\n\n          -  Patient must have received at least one prior treatment for recurrent, metastatic and\n             /or locally advanced disease and for whom no standard therapy options are anticipated\n             to result in a durable remission.\n\n          -  Patient must have progressive and measurable disease per RECIST 1.1. or other\n             appropriate hematological response criteria.\n\n          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1\n\n        Exclusion Criteria:\n\n          -  Patient has received prior treatment with LGX818.\n\n          -  Patients with Central Nerve System (CNS) metastasis or leptomeningeal carcinomatosis.\n\n          -  Patient has received chemotherapy or other anticancer therapy \u2264 4 weeks (6 weeks for\n             nitrosourea, antibodies or mitomycin-C) prior to starting study drug.\n\n          -  Patients with acute or chronic pancreatitis.\n\n          -  Patients with impaired cardiac function or clinically significant cardiac diseases.\n\n          -  Patients with another primary malignancy within 3 years prior to starting study\n             treatment, with the exception of adequately treated basal cell carcinoma, squamous\n             cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the\n             uterine cervix."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981187", 
            "org_study_id": "CLGX818AUS03"
        }, 
        "intervention": {
            "arm_group_label": "LGX818", 
            "description": "LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg  capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.", 
            "intervention_name": "LGX818", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "link": {
            "url": "http://www.signaturetrial.com"
        }, 
        "location": [
            {
                "contact": {
                    "phone": "+1 479 872 8130"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "Highlands Oncology Group Highlands Oncology Group (22)"
                }, 
                "investigator": {
                    "last_name": "Joseph Thaddeus Beck", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "310-522-9999"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90403"
                    }, 
                    "name": "Sarcoma Oncology Center"
                }, 
                "investigator": {
                    "last_name": "Sant Chawla", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "203-852-2996"
                }, 
                "facility": {
                    "address": {
                        "city": "Norwalk", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06856"
                    }, 
                    "name": "Whittingham Cancer Center Norwalk Hospital"
                }, 
                "investigator": {
                    "last_name": "Richard C. Frank", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "561-366-4100"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33901"
                    }, 
                    "name": "Florida Cancer Specialists Florida Cancer Specialists (31"
                }, 
                "investigator": {
                    "last_name": "Todd L. Gersten", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "773-702-4399"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Medical Center, Hematology & Oncology University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Ravi Salgia", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "312-695-0184"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University Developmental Therapeutics Ins"
                }, 
                "investigator": {
                    "last_name": "Melissa Johnson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "503-494-8534"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University OHSU Knight Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Matthew Taylor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "215-746-6344"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania Presbyterian Medical Center University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Marcia S. Brose", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "832-824-5383"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }, 
                    "name": "Oncology Consultants Oncology Group"
                }, 
                "investigator": {
                    "last_name": "Julio Peguero", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Enrollment Center", 
            "phone": "1-855-744-6727"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical benefit rate for patients with solid tumors will be assessed using RECIST 1.1 and will include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria will apply", 
            "measure": "Clinical benefit rate associated with LGX818 treatment", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Response (OR) of Partial Response (PR) or greater based on local investigator assessment. For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR and/or PR. For hematologic tumors other appropriate hematological response criteria will apply", 
                "measure": "Overall Response (OR) or Partial Response (PR) or greater", 
                "safety_issue": "No", 
                "time_frame": "baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months"
            }, 
            {
                "description": "Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause", 
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until death, assessed up to 24 months"
            }, 
            {
                "description": "Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until death, assessed up to 36 months"
            }, 
            {
                "description": "The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months"
            }, 
            {
                "description": "Safety and tolerability will be will be based on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate.", 
                "measure": "Number of participants with adverse events as a measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}